Mayne Pharma acquires new cancer products

Mayne Pharma, the Australian drugs manufacturer, has acquired two oncology products from SuperGen.

The company has gain the North American rights to Nipent, a treatment for hairy cell leukaemia, and SurfaceSafe, a towel system to decontaminate surfaces after the use of chemotherapy products. Mayne has paid SuperGen $14 million (7.7 million pounds), which could rise to $34 million, depending on certain milestones and the performance of the products.

Mayne Pharma’s chief executive officer and managing director, Dr Thierry Soursac, stated: “A key element of Mayne Pharma’s new strategy, presented last month, is to acquire niche marketed or close-to-market proprietary products that strengthen our oncology focus and leverage our development, manufacturing and marketing capabilities.

“The addition of Nipent, therefore, fits our strategy perfectly, building on our core oncology capability, particularly in the important US market.”

“In addition, since Nipent is a proprietary product, this transaction will raise Mayne Pharma’s profile with key customers and opinion leaders, further strengthening our position,” he concluded.

Mayne also revealed that it was in talks with SuperGen to acquire mitomycin, a cytotoxic cancer therapy for the US market. The company’s Europe, Middle East and Africa headquarters are based in Royal Leamington Spa, Warwickshire. Mayne operates in several disease areas in over 65 countries and produces both injectable generic products and proprietary drugs. The product pipeline expands beyond five years, according to Mayne.

© Adfero Ltd